Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inflammatory reactions mimic residual or recurrent lymphoma on [18F]FDG-PET/CT after CD19-directed CAR T-cell therapy.
de Boer JW, Pennings ERA, Kleinjan A, van Doesum JA, Spanjaart AM, Mutsaers PGNJ, Jak M, van der Poel MWM, Kuipers MT, Adam JA, Diepstra A, Koens L, van Dorp S, Vermaat JSP, Niezink AGH, Kersten MJ, van Meerten T. de Boer JW, et al. Among authors: diepstra a. Blood Adv. 2023 Nov 14;7(21):6710-6716. doi: 10.1182/bloodadvances.2023010665. Blood Adv. 2023. PMID: 37639324 Free PMC article. No abstract available.
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach.
de Jong MRW, Visser L, Huls G, Diepstra A, van Vugt M, Ammatuna E, van Rijn RS, Vellenga E, van den Berg A, Fehrmann RSN, van Meerten T. de Jong MRW, et al. Among authors: diepstra a. PLoS One. 2018 Feb 28;13(2):e0193098. doi: 10.1371/journal.pone.0193098. eCollection 2018. PLoS One. 2018. PMID: 29489886 Free PMC article.
High prevalence of MYD88 and CD79B mutations in intravascular large B-cell lymphoma.
Schrader AMR, Jansen PM, Willemze R, Vermeer MH, Cleton-Jansen AM, Somers SF, Veelken H, van Eijk R, Kraan W, Kersten MJ, van den Brand M, Stevens WBC, de Jong D, Abdul Hamid M, Tanis BC, Posthuma EFM, Nijland M, Diepstra A, Pals ST, Cleven AHG, Vermaat JSP. Schrader AMR, et al. Among authors: diepstra a. Blood. 2018 May 3;131(18):2086-2089. doi: 10.1182/blood-2017-12-822817. Epub 2018 Mar 7. Blood. 2018. PMID: 29514783 Free article. No abstract available.
Tumour necrosis as assessed with 18F-FDG PET is a potential prognostic marker in diffuse large B cell lymphoma independent of MYC rearrangements.
Kahle XU, Hovingh M, Noordzij W, Seitz A, Diepstra A, Visser L, van den Berg A, van Meerten T, Huls G, Boellaard R, Kwee TC, Nijland M. Kahle XU, et al. Among authors: diepstra a. Eur Radiol. 2019 Nov;29(11):6018-6028. doi: 10.1007/s00330-019-06178-9. Epub 2019 Apr 26. Eur Radiol. 2019. PMID: 31028445 Free PMC article.
Interim thymus and activation regulated chemokine versus interim 18 F-fluorodeoxyglucose positron-emission tomography in classical Hodgkin lymphoma response evaluation.
Plattel WJ, Visser L, Diepstra A, Glaudemans AWJM, Nijland M, van Meerten T, Kluin-Nelemans HC, van Imhoff GW, van den Berg A. Plattel WJ, et al. Among authors: diepstra a. Br J Haematol. 2020 Jul;190(1):40-44. doi: 10.1111/bjh.16514. Epub 2020 Feb 27. Br J Haematol. 2020. PMID: 32106342 Free PMC article.
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study.
Kersten MJ, Driessen J, Zijlstra JM, Plattel WJ, Morschhauser F, Lugtenburg PJ, Brice P, Hutchings M, Gastinne T, Liu R, Burggraaff CN, Nijland M, Tonino SH, Arens AIJ, Valkema R, van Tinteren H, Lopez-Yurda M, Diepstra A, De Jong D, Hagenbeek A. Kersten MJ, et al. Among authors: diepstra a. Haematologica. 2021 Apr 1;106(4):1129-1137. doi: 10.3324/haematol.2019.243238. Haematologica. 2021. PMID: 32273476 Free PMC article. Clinical Trial.
Molecular imaging in lymphoma beyond 18F-FDG-PET: understanding the biology and its implications for diagnostics and therapy.
Kahle XU, Montes de Jesus FM, Glaudemans AWJM, Lub-de Hooge MN, Jorritsma-Smit A, Plattel WJ, van Meerten T, Diepstra A, van den Berg A, Kwee TC, Noordzij W, de Vries EGE, Nijland M. Kahle XU, et al. Among authors: diepstra a. Lancet Haematol. 2020 Jun;7(6):e479-e489. doi: 10.1016/S2352-3026(20)30065-X. Lancet Haematol. 2020. PMID: 32470439 Review.
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.
Chamuleau MED, Burggraaff CN, Nijland M, Bakunina K, Mous R, Lugtenburg PJ, Dierickx D, van Imhoff GW, Vermaat JSP, Marijt EAF, Visser O, Mandigers C, Bilgin YM, Beeker A, Durian MF, van Rees B, Bohmer LH, Tick LW, Boersma RS, Snijders TJF, Schouten HC, Koene HR, de Jongh E, Hijmering N, Diepstra A, van den Berg A, Arens AIJ, Huijbregts J, Hoekstra O, Zijlstra JM, de Jong D, Kersten MJ. Chamuleau MED, et al. Among authors: diepstra a. Haematologica. 2020 Dec 1;105(12):2805-2812. doi: 10.3324/haematol.2019.238162. Haematologica. 2020. PMID: 33256379 Free PMC article. Clinical Trial.
189 results